Skip directly to content

Our partners

Strengthening R&D through Collaboration

In addition to conducting research at our R&D centers, we have also multiplied our innovative strength by partnering with medical institutions, health foundations and research organizations to develop new medicines and vaccines that the world needs.

Here are some of our collaborative partners:
Bristol-Myers Squibb (a global biopharmaceutical company)
Development of medicine for treatment of moderate-to-severe rheumatoid arthritis

University of Cambridge’s Cardiovascular Epidemiology Unit
Development of medicines for cardiovascular diseases

Repligen Corporation (a life sciences company specializing in the development and production of products used in the manufacturing of biological drugs)
Development of treatment solutions for spinal muscular atrophy

Cystic Fibrosis Foundation Therapeutics or CFFT (the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.
Development of new treatments for the most common mutation of cystic fibrosis or Delta F508

Philogen S.p.A. (a biotechnology company specializing in the discovery and development of novel biopharmaceutical products for the treatment certain diseases that are characterized by angiogenesis, the proliferation of newly formed blood vessels)
Development of immunoregulatory therapy for autoimmune diseases

Alliance for Lupus Research (a New York-based a national voluntary health organization)
Development of new therapeutic treatment for chronic autoimmune diseases.

Institut du Cerveau et de la Moelle épinière (a medical scientific center in France)
Research on treatment solutions for certain neurodegenerative diseases with significant unmet medical needs such as Alzheimer’s, Parkinson’s and Huntington’s diseases.

European Autism Interventions (the largest single grant for autism research in the world)
Research on new methods to development drugs for autism spectrum disorders (ASDs).

French National Cancer Institute (a health research institute in France)
Development of personalized cancer therapies.